Dr. Joshua Bederson, a renowned neurosurgeon at The Mount Sinai Hospital, embarked on a groundbreaking surgery in April that showcased Precision Neuroscience’s innovative brain-computer interface (BCI) technology. With over 6,500 procedures under his belt, Bederson prepared to remove a benign brain tumor while simultaneously testing Precision’s electrode arrays. These arrays, thinner than a human hair,… Continue reading Here’s what it’s like inside the operating room when someone gets a brain implant

Big pharmaceutical companies are investing heavily in targeted radiopharmaceutical therapy, considering it a significant opportunity in cancer treatment. This therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. Analysts at RBC Capital Markets estimate a market opportunity of $25 billion for this space, emphasizing its early-stage development and potential… Continue reading This up-and-coming cancer treatment could be a $25 billion market opportunity — it’s already a hotbed for M&A

Pfizer has unveiled a new multiyear cost-cutting initiative aimed at bolstering its financial standing following a significant downturn in its Covid-related business. This program, supplementing a previously announced $4 billion cost reduction plan, will initially focus on operational efficiencies, with anticipated savings of approximately $1.5 billion by the end of 2027. While this move is… Continue reading Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts

New strains of Covid-19, collectively known as the FLiRT variants, are spreading globally and raising concerns about a potential summer spike in cases. These new variants are descendants of the previously dominant JN.1 variant, an offshoot of Omicron. The FLiRT variants, which include strains like KP.2 and KP.1.1, have been independently picking up similar mutations.… Continue reading New Covid FLiRT variants spark concerns of a summer spike

AstraZeneca announced ambitious plans to increase its total revenue to $80 billion by 2030, a 75% rise from $45.8 billion in 2023. The company’s Chief Financial Officer, Aradhana Sarin, expressed confidence in achieving this goal due to the breadth and scale of their current portfolio. AstraZeneca’s growth strategy focuses on its oncology, biopharmaceuticals, and rare… Continue reading AstraZeneca targets $80 billion in total revenue by 2030 in ‘post-Covid era’

Halifax, Nova Scotia–(Newsfile Corp. – May 21, 2024) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) to be the Company’s Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical Oncologist at the QEII Health Sciences Centre… Continue reading Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent

Roche announced promising results from an early-stage trial of its experimental weight loss drug, CT-388, marking a significant stride in its endeavor to penetrate the burgeoning obesity treatment market. Acquired through its nearly $3 billion takeover of Carmot Therapeutics in December, the drug is poised to challenge established players like Novo Nordisk and Eli Lilly… Continue reading Roche says weight loss drug shows promising results in early trial

Alpha Cognition Inc. has released financial results for the first quarter of 2024 and has provided a corporate update. “Alpha Cognition continues to progress in its review process with FDA for ALPHA-1062, which is under review with FDA as a treatment for mild-to-moderate Alzheimer’s disease. Our team continues to plan for commercialization activities, progress on… Continue reading ALPHA COGNITION ANNOUNCES FIRST QUARTER OF 2024 RESULTS AND PROVIDES CORPORATE UPDATE

Walgreens announced its plan to introduce a more affordable version of the over-the-counter opioid overdose reversal spray naloxone, aiming to enhance accessibility to this life-saving medication across the United States. As the nation continues to grapple with the devastating effects of the opioid epidemic, characterized by alarmingly high drug fatality rates, Walgreens seeks to play… Continue reading Walgreens to offer its own cheaper version of opioid overdose reversal drug naloxone

A new analysis of Novo Nordisk’s obesity drug Wegovy reveals promising long-term effects, with patients maintaining an average 10% weight loss over four years, the longest clinical trial on the treatment to date. Additionally, a separate analysis from the same trial indicates Wegovy reduces the risk of heart disease, irrespective of a patient’s weight. These… Continue reading People on Novo Nordisk’s Wegovy maintain weight loss for up to four years, study says

SUNNYVALE, Calif., May 13, 2024 /PRNewswire/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended March 31, 2024, reporting significantly reduced costs and further progress in its… Continue reading WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Toronto, Ontario – TheNewswire – May 13, 2024– Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) announces that it has closed the insider led first tranche of its previously announced non-brokered private placement of unsecured convertible debentures (“Debentures”) for gross proceeds of $941,000. Ventripoint has issued an aggregate of $941,000 principal amount of Debentures with… Continue reading Ventripoint Announces Closing of First Tranche of Non-Brokered Convertible Debenture Private Placement